Collaboration Agreements (Tables)

3 Months Ended

Mar. 31, 2016

Collaboration Agreement [Abstract]

Collaboration revenue with related party

The collaboration revenue the Company earned from Sanofi is detailed below:

	Three Months Ended March 31,
Sanofi Collaboration Revenue	2016			2015
Antibody:
Reimbursement of Regeneron research and development expenses	$	193,602		$	168,820
Reimbursement of Regeneron commercialization-related expenses	73,274			8,458
Regeneron's share of losses in connection with commercialization of antibodies	(99,422		)	(22,405		)
Other	2,965			2,561
Total Antibody	170,419			157,434
Immuno-oncology:
Reimbursement of Regeneron research and development expenses	29,275			—
Other	20,000			—
Total Immuno-oncology	49,275			—
ZALTRAP®:
Reimbursement of Regeneron research and development expenses	—			686
Other	—			15,236
Total ZALTRAP	—			15,922
	$	219,694		$	173,356

Collaboration revenue

The collaboration revenue the Company earned from Bayer is detailed below:

	Three Months Ended March 31,
Bayer Collaboration Revenue	2016		2015
EYLEA:
Regeneron's net profit in connection with commercialization of EYLEA outside the United States	$	145,835	$	89,426
Sales milestones	—		15,000
Cost-sharing of Regeneron EYLEA development expenses	2,743		2,657
Other	26,492		12,912
Total EYLEA	175,070		119,995
PDGFR-beta antibody:
Cost-sharing of rinucumab/aflibercept (REGN2176-3) development expenses	1,896		1,254
Other	2,626		2,597
Total PDGFR-beta	4,522		3,851
	$	179,592	$	123,846